Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review

Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review

Aims and backgroundA number of population pharmacokinetic (PPK) models of anti-programmed cell death-1 (PD-1) monoclonal antibodies (mAbs) in multiple tumor types have been published to characterize the influencing factors of their pharmacokinetics. This review described PPK models of anti-PD-1 mAbs...

Full description

Bibliographic Details
Main Authors:	Jingyuan Shang, Lin Huang, Jing Huang, Xiaolei Ren, Yi Liu, Yufei Feng
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2022-08-01
Series:	Frontiers in Immunology
Subjects:	anti-PD-1 mAbs immune checkpoint inhibitors population pharmacokinetics PPK model systematic review
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.871372/full

Similar Items

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC
by: Cinzia Vetrei, et al.
Published: (2021-12-01)

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments
by: Cinzia Vetrei, et al.
Published: (2021-06-01)

New Insights on the Role of Anti-PD-L1 and Anti-CTLA-4 mAbs on Different Lymphocytes Subpopulations in TNBC
by: Rosa Rapuano Lembo, et al.
Published: (2022-10-01)

A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti–PD-1 mAb, in patients with advanced or metastatic solid tumors
by: Zhiyu Huang, et al.
Published: (2023-10-01)

Implementation of QbD strategies in the inoculum expansion of a mAb production process
by: Ole Jacob Böhl, et al.
Published: (2021-03-01)

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells
by: Margherita Passariello, et al.
Published: (2020-08-01)

IL36 Cooperates With Anti-CTLA-4 mAbs to Facilitate Antitumor Immune Responses
by: Qiuxia Qu, et al.
Published: (2020-04-01)

Therapeutic Potential of HLA-I Polyreactive mAbs Mimicking the HLA-I Polyreactivity and Immunoregulatory Functions of IVIg
by: Mepur H. Ravindranath, et al.
Published: (2021-06-01)

Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies
by: Chen DT, et al.
Published: (2019-02-01)

Monoclonal Antibody Therapies against Anthrax
by: Zhaochun Chen, et al.
Published: (2011-08-01)

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs
by: Josée Golay, et al.
Published: (2020-10-01)

An eNAMPT-neutralizing mAb reduces post-infarct myocardial fibrosis and left ventricular dysfunction
by: Zhonglin Liu, et al.
Published: (2024-01-01)

Apatinib combined with PD-1 antibody for third-line or later treatment of advanced gastric cancer
by: Qingli Cui, et al.
Published: (2022-10-01)

Homogeneous antibody-drug conjugates: DAR 2 anti-HER2 obtained by conjugation on isolated light chain followed by mAb assembly
by: Mercè Farràs, et al.
Published: (2020-01-01)

Three neutralizing mAbs induced by MPXV A29L protein recognizing different epitopes act synergistically against orthopoxvirus
by: Mengjun Li, et al.
Published: (2023-12-01)

Modulating the tumor microenvironment improves antitumor effect of anti-PD-L1 mAb in breast cancer
by: Xiuying Li, et al.
Published: (2023-03-01)

Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies
by: Boris Grinshpun, et al.
Published: (2021-01-01)

Enhancing Antibody Exposure in the Central Nervous System: Mechanisms of Uptake, Clearance, and Strategies for Improved Brain Delivery
by: Kelly Schwinghamer, et al.
Published: (2023-10-01)

Population Pharmacokinetics of Polymyxin B and Dosage Optimization in Renal Transplant Patients
by: Ying Li, et al.
Published: (2021-08-01)

How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca<sup>2+</sup>
by: Ronald P. Taylor, et al.
Published: (2020-09-01)

Treatment of Hepatocellular Carcinoma by Intratumoral Injection of 125I-AA98 mAb and Its Efficacy Assessments by Molecular Imaging
by: Jun Zhou, et al.
Published: (2019-11-01)

Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors
by: Sho Yoshimoto, et al.
Published: (2023-12-01)

Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting
by: Thomas Kissner, et al.
Published: (2021-01-01)

Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
by: Sandor Schokker, et al.
Published: (2020-01-01)

Effect of molecular size on interstitial pharmacokinetics and tissue catabolism of antibodies
by: Hanine Rafidi, et al.
Published: (2022-12-01)

Ablation Reboots the Response in Advanced Hepatocellular Carcinoma With Stable or Atypical Response During PD-1 Therapy: A Proof-of-Concept Study
by: Ning Lyu, et al.
Published: (2020-10-01)

Real-world evidence on the economic implications of CGRP-mAbs as preventive treatment of migraine
by: Nikolaj Siersbæk, et al.
Published: (2023-07-01)

Concentration Effects in the Interaction of Monoclonal Antibodies (mAbs) with their Immediate Environment Characterized by EPR Spectroscopy
by: Haleh H. Haeri, et al.
Published: (2019-07-01)

Harnessing CD16-Mediated NK Cell Functions to Enhance Therapeutic Efficacy of Tumor-Targeting mAbs
by: Cristina Capuano, et al.
Published: (2021-05-01)

Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal
by: Yan Tereshko, et al.
Published: (2023-11-01)

Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
by: Masaud Shah, et al.
Published: (2020-01-01)

Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis
by: Datian Chen, et al.
Published: (2018-10-01)

Clinical evaluation of super-responders vs. non-responders to CGRP(-receptor) monoclonal antibodies: a real-world experience
by: Bianca Raffaelli, et al.
Published: (2023-02-01)

Engineering death resistance in CHO cells for improved perfusion culture
by: Michael A. MacDonald, et al.
Published: (2022-12-01)

Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content
by: Sean Chia, et al.
Published: (2023-07-01)

Progress of research on PD-1/PD-L1 in leukemia
by: Huizhen Cao, et al.
Published: (2023-09-01)

Adhesion Molecule Profile and the Effect of Anti-VLA-4 mAb Treatment in Experimental Autoimmune Encephalomyelitis, a Mouse Model of Multiple Sclerosis
by: Grażyna Pyka-Fościak, et al.
Published: (2022-04-01)

Immune Checkpoint Inhibitors in Colorectal Cancer: Challenges and Future Prospects
by: Shima Makaremi, et al.
Published: (2021-08-01)

DNA-delivered monoclonal antibodies targeting the p53 R175H mutant epitope inhibit tumor development in mice
by: Dafei Chai, et al.
Published: (2024-07-01)

Pharmacokinetics of monoclonal antibodies and Fc-fusion proteins
by: Liming Liu
Published: (2017-04-01)